215 related articles for article (PubMed ID: 8993250)
41. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass.
Hatori N; Yoshizu H; Haga Y; Kusama Y; Takeshima S; Segawa D; Tanaka S
Artif Organs; 1994 Dec; 18(12):904-10. PubMed ID: 7887827
[TBL] [Abstract][Full Text] [Related]
42. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators.
de Vroege R; van Oeveren W; van Klarenbosch J; Stooker W; Huybregts MAJM; Hack CE; van Barneveld L; Eijsman L; Wildevuur CRH
Anesth Analg; 2004 Jun; 98(6):1586-1594. PubMed ID: 15155310
[TBL] [Abstract][Full Text] [Related]
43. Complement activation during cardiopulmonary bypass: effects of immobilized heparin.
Pekna M; Hagman L; Haldén E; Nilsson UR; Nilsson B; Thelin S
Ann Thorac Surg; 1994 Aug; 58(2):421-4. PubMed ID: 8067842
[TBL] [Abstract][Full Text] [Related]
44. Influence of PMEA-coated bypass circuits on perioperative inflammatory response.
Ninomiya M; Miyaji K; Takamoto S
Ann Thorac Surg; 2003 Mar; 75(3):913-7; discussion 917-8. PubMed ID: 12645716
[TBL] [Abstract][Full Text] [Related]
45. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
[TBL] [Abstract][Full Text] [Related]
46. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery.
van der Kamp KW; van Oeveren W
Int J Artif Organs; 1993 Dec; 16(12):836-42. PubMed ID: 8175200
[TBL] [Abstract][Full Text] [Related]
47. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits.
Olsson C; Siegbahn A; Haldén E; Nilsson B; Venge P; Thelin S
Ann Thorac Surg; 2000 Mar; 69(3):743-9. PubMed ID: 10750754
[TBL] [Abstract][Full Text] [Related]
48. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass.
Boonstra PW; Gu YJ; Akkerman C; Haan J; Huyzen R; van Oeveren W
J Thorac Cardiovasc Surg; 1994 Jan; 107(1):289-92. PubMed ID: 8283898
[TBL] [Abstract][Full Text] [Related]
49. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits.
Baufreton C; Moczar M; Intrator L; Jansen PG; te Velthuis H; Le Besnerais P; Farcet JP; Wildevuur CR; Loisance DY
Perfusion; 1998 Nov; 13(6):419-27. PubMed ID: 9881389
[TBL] [Abstract][Full Text] [Related]
50. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
51. Brain injury and neuropsychological outcome after coronary artery surgery are affected by complement activation.
Baufreton C; Allain P; Chevailler A; Etcharry-Bouyx F; Corbeau JJ; Legall D; de Brux JL
Ann Thorac Surg; 2005 May; 79(5):1597-605. PubMed ID: 15854939
[TBL] [Abstract][Full Text] [Related]
52. Heparin-coated circuits reduce occult myocardial damage during CPB: a randomized, single blind clinical trial.
Belboul A; Löfgren C; Storm C; Jungbeck M
Eur J Cardiothorac Surg; 2000 May; 17(5):580-6. PubMed ID: 10814923
[TBL] [Abstract][Full Text] [Related]
53. Influence of two blood conservation techniques (cardiotomy reservoir versus cell-saver) on biocompatibility of the heparin coated cardiopulmonary bypass circuit during coronary revascularization surgery.
Borowiec JW; Bozdayi M; Jaramillo A; Nilsson L; Venge P; Henze A
J Card Surg; 1997; 12(3):190-7. PubMed ID: 9395949
[TBL] [Abstract][Full Text] [Related]
54. Effects of heparin-coating of cardiopulmonary bypass circuits on leukocytes during simulated extracorporeal circulation.
Borowiec J; Jaramillo A; Venge P; Nilsson L; Thelin S
Cardiovasc Surg; 1997 Dec; 5(6):568-73. PubMed ID: 9423940
[TBL] [Abstract][Full Text] [Related]
55. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
[TBL] [Abstract][Full Text] [Related]
56. Gene expression changes in leukocytes during cardiopulmonary bypass are dependent on circuit coating.
Seeburger J; Hoffmann J; Wendel HP; Ziemer G; Aebert H
Circulation; 2005 Aug; 112(9 Suppl):I224-8. PubMed ID: 16159821
[TBL] [Abstract][Full Text] [Related]
57. Activation of neutrophils and monocytes by a leukocyte-depleting filter used throughout cardiopulmonary bypass.
Ilmakunnas M; Pesonen EJ; Ahonen J; Rämö J; Siitonen S; Repo H
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):851-9. PubMed ID: 15821654
[TBL] [Abstract][Full Text] [Related]
58. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
[TBL] [Abstract][Full Text] [Related]
59. Clinical and biomaterial evaluation of a new condensed dual-function extracorporeal circuit in reoperation for coronary artery bypass surgery.
Gunaydin S; McCusker K; Vijay V
Int J Artif Organs; 2009 Nov; 32(11):802-10. PubMed ID: 20020412
[TBL] [Abstract][Full Text] [Related]
60. Specific complement inhibition with heparin-coated extracorporeal circuits.
te Velthuis H; Jansen PG; Hack CE; Eijsman L; Wildevuur CR
Ann Thorac Surg; 1996 Apr; 61(4):1153-7. PubMed ID: 8607674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
